Allergy Immunotherapy: All Modalities Compared by Evidence
Allergy immunotherapy covers four routes — shots, sublingual tablets, drops, and oral food immunotherapy — each targeting the same immune pathways but differing in safety, convenience, cost, and FDA status. A 2007 Cochrane review found SCIT reduces rhinitis symptoms by 33% and medication use by 36%; a 2015 network meta-analysis found SLIT tablets equally effective for grass pollen. No single modality is optimal for every patient.
10 peer-reviewed sources
Allergy immunotherapy includes shots, sublingual tablets, drops, and oral food immunotherapy. Shots and tablets show comparable efficacy for most allergens; tablets offer safer at-home dosing, while shots suit polysensitized patients needing custom multi-allergen formulations.
Which Immunotherapy Route Is Right for You?
Allergy immunotherapy (AIT) is the only category of allergy treatment classified as disease-modifying by the World Health Organization — meaning it changes the underlying allergic disease rather than simply suppressing symptoms. Unlike antihistamines or nasal steroids, which must be taken continuously to maintain effect, a completed 3-to-5-year course of AIT can provide symptom relief lasting 3 to 12 years after treatment ends.
The term immunotherapy encompasses several distinct modalities. Subcutaneous immunotherapy (SCIT), better known as allergy shots, has the longest evidence base — over 100 years of clinical use and 51 randomized controlled trials supporting its use for rhinitis. Sublingual immunotherapy tablets (SLIT-tablets) are FDA-approved products (Grastek, Ragwitek, Oralair, Odactra) that treat specific single allergens and can be taken at home. Sublingual drops are compounded off-label in the US but widely used — about 30-40% of US allergists offer them. A real-world Curex study of 2,897 patients on at-home sublingual immunotherapy (Tharpe et al., Frontiers in Allergy, 2026, peer-reviewed) found that clinically meaningful symptom improvement rose to 45% of patients by two years, with quality-of-life improvement reaching 90.7% and adherence over 90%. Oral immunotherapy for peanut allergy had one FDA-approved product, Palforzia, until it was withdrawn from the US market on 31 July 2026; it now continues off-label. Emerging approaches — intralymphatic immunotherapy (ILIT), epicutaneous patches (EPIT), and peptide vaccines — remain investigational.
Before selecting any immunotherapy route, identifying your specific allergen triggers through comprehensive testing is the essential first step. At-home allergy testing services like Curex can screen for 40+ allergens with results in about a week, providing the clinical foundation for selecting the modality and route that fits your sensitization profile and lifestyle.
No immunotherapy modality is universally superior. The right choice depends on your allergen profile, tolerance for clinic visits, needle preference, insurance coverage, and commitment to a multi-year treatment course.
The Shared Biology Behind All Immunotherapy Routes
Despite differences in delivery route and allergen dose, all forms of allergen immunotherapy converge on the same core immune mechanism: induction of peripheral tolerance through regulatory T cells (Tregs), a shift from IgE-dominant to IgG4-dominant antibody responses, and suppression of the mast cell and basophil reactivity that drives allergic symptoms. The key distinction between routes lies in which dendritic cells are engaged and what dose is required to activate them. SCIT engages dermal myeloid dendritic cells, which are highly efficient antigen presenters — enabling relatively low allergen doses to trigger a tolerogenic immune response. SLIT exploits oral mucosal Langerhans-like dendritic cells, which are similarly tolerogenic but require 50-100 times higher allergen doses to achieve comparable immunologic results. This dose difference explains both SLIT's superior safety profile (less systemic allergen exposure per dose) and its requirement for daily dosing rather than weekly injections.
Allergen Identification and Testing
Comprehensive allergy testing identifies which specific IgE-mediated triggers are driving your symptoms. Skin-prick testing or serum-specific IgE measurements quantify sensitization and determine which allergens should be included in the immunotherapy protocol. Accurate allergen selection is the single largest predictor of treatment success.
Dose Escalation and Early Desensitization
Whether by injection or sublingual route, treatment begins with very small allergen doses that are gradually increased. Within hours of the first doses, mast cells and basophils begin upregulating histamine receptor 2, suppressing allergic degranulation. This early desensitization occurs before the slower adaptive immune changes become measurable.
Regulatory T Cell Induction and IgG4 Rise
Over weeks to months, FOXP3+ regulatory T cells and IL-10-producing Tr1 cells expand, secreting cytokines that suppress IgE production and switch B cells toward IgG4 antibody production. Allergen-specific IgG4 rises 10 to 100-fold during successful AIT and acts as a blocking antibody, preventing IgE from triggering mast cell activation. This is the central molecular mechanism of clinical tolerance.
Sustained Tolerance and Disease Modification
After 3 or more years of treatment, the immunologic changes become self-sustaining: IgG4 levels remain elevated, tissue eosinophil counts fall, and regulatory ILC2 subsets emerge. Durham et al. (NEJM 1999) demonstrated that symptom relief from grass-pollen SCIT persisted at least 3 years after stopping treatment, confirming true disease modification rather than just symptom suppression.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
What the Evidence Actually Shows by Allergen and Modality
SCIT efficacy varies substantially across allergen categories. The evidence is strongest for grass pollen and house dust mites, where multiple large RCTs and Cochrane systematic reviews confirm meaningful, sustained symptom reduction. Evidence is moderate for cat dander, birch, ragweed, and Alternaria mold. Evidence is weak or negative for cockroach (CRITICAL trial 2024 failed its primary endpoint) and dog dander (limited standardized extract availability). These differences matter when choosing a treatment plan — patients sensitized only to well-evidenced allergens are better candidates than those whose primary triggers have weak AIT evidence. Across allergens with strong evidence, SCIT produces roughly a one-third reduction in nasal symptom scores. Matricardi et al. (JACI 2011) calculated that grass SCIT reduces total nasal symptom scores by 34.7% relative to placebo — comparable to intranasal corticosteroids (31.7%) and substantially better than antihistamines (12%) or leukotriene antagonists (6.3%). The disease-modifying advantage of AIT becomes apparent only after stopping treatment, when pharmacotherapy symptoms immediately return while AIT benefits persist.
Success Rate by Duration
Compare immunotherapy options, then check your eligibility
Curex offers at-home allergy shot treatment with clinician support, serum delivered to your door, and no weekly office visits.
See if you qualifyCurex allergy shot serum is compounded at a specialty pharmacy for each patient, and the FDA does not review compounded products for safety or efficacy.
Allergy Immunotherapy Modalities: A Head-to-Head Comparison
The practical question for most patients is which modality they will consistently adhere to over 3-5 years. Real-world adherence is challenging for both — one analysis found 3-year adherence of roughly 23% for SCIT and 7% for SLIT (Kiel et al., JACI 2013). Both SCIT and SLIT are effective and generally safe; the right choice depends on individual lifestyle factors and preferences, and at-home options for either modality can improve convenience and reduce the weekly-visit burden that drives dropout.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
At-Home Allergy Shots (SCIT) — CurexBest | Symptom reduction SMD -0.73; 51 RCTs; strongest evidence for grass, dust mites, ragweed, cat, Alternaria | 3-5 years (weekly buildup, ongoing maintenance) | $3,000-$20,000 total (varies by insurance) | Self-administered at home with Curex: weekly build-up for 3-7 months, then on a schedule individualized by your allergist; the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff, with a brief self-observation after each | Systemic reactions 0.1% per injection; fatal anaphylaxis ~1 per 2.5 million injections historically; at home with Curex, a USP <797> sterile-compounded serum, a prescribed epinephrine auto-injector confirmed on hand, and Virtual Shot Room–supervised first and dose-change injections by trained Curex clinical staff keep it safe for eligible patients |
SLIT Tablets (FDA-Approved) | Comparable to SCIT for grass (Nelson 2015 network MA); FDA-approved for 4 allergens: grass, ragweed, 5-grass mix, dust mite | 3 years (daily home dosing) | $5,300-$13,000 retail; $300-$600 annually with manufacturer copay cards | Daily tablet dissolved under tongue at home; first dose in clinic only; covers only ONE allergen per product | Zero confirmed fatalities worldwide; mild local oral reactions in 25-67%; anaphylaxis 0.02% of patients in pooled trials |
SLIT Drops (Compounded, Off-Label) | Broadly comparable to tablets based on indirect data; off-label in US, not FDA-approved; can treat multiple allergens | 3 years (daily home dosing) | $1,200-$3,600 typical for telehealth services; not typically covered by insurance | Daily drops at home; no clinic visits required after initial assessment; can address multiple allergens in a single formulation | No confirmed fatalities; local oral reactions common and mild; anaphylaxis case reports rare; less standardized than tablets |
OIT (peanut; Palforzia withdrawn 2026) | FDA-approved January 2020; achieves desensitization (increased threshold), not full tolerance; for peanut allergy only | Ongoing (desensitization maintained, not a cure) | $10,000-$15,000+; insurance coverage variable | Daily oral dosing at home after in-office buildup; dose escalation visits required; ongoing maintenance essential | Systemic reactions more common than environmental AIT; abdominal pain frequent; EoE risk; requires epinephrine prescription |
Antihistamines (OTC Symptom Control) | Symptom relief only; no disease modification; about 12% reduction in nasal symptom scores (Matricardi 2011) | Ongoing (symptoms return on stopping) | $300-$900 OTC | Daily pill; available without prescription; no clinic visits | Non-sedating second-generation: generally safe; no immunological benefit; no effect on disease progression |
- Efficacy
- Symptom reduction SMD -0.73; 51 RCTs; strongest evidence for grass, dust mites, ragweed, cat, Alternaria
- Duration
- 3-5 years (weekly buildup, ongoing maintenance)
- Cost (5yr)
- $3,000-$20,000 total (varies by insurance)
- Convenience
- Self-administered at home with Curex: weekly build-up for 3-7 months, then on a schedule individualized by your allergist; the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff, with a brief self-observation after each
- Safety
- Systemic reactions 0.1% per injection; fatal anaphylaxis ~1 per 2.5 million injections historically; at home with Curex, a USP <797> sterile-compounded serum, a prescribed epinephrine auto-injector confirmed on hand, and Virtual Shot Room–supervised first and dose-change injections by trained Curex clinical staff keep it safe for eligible patients
- Efficacy
- Comparable to SCIT for grass (Nelson 2015 network MA); FDA-approved for 4 allergens: grass, ragweed, 5-grass mix, dust mite
- Duration
- 3 years (daily home dosing)
- Cost (5yr)
- $5,300-$13,000 retail; $300-$600 annually with manufacturer copay cards
- Convenience
- Daily tablet dissolved under tongue at home; first dose in clinic only; covers only ONE allergen per product
- Safety
- Zero confirmed fatalities worldwide; mild local oral reactions in 25-67%; anaphylaxis 0.02% of patients in pooled trials
- Efficacy
- Broadly comparable to tablets based on indirect data; off-label in US, not FDA-approved; can treat multiple allergens
- Duration
- 3 years (daily home dosing)
- Cost (5yr)
- $1,200-$3,600 typical for telehealth services; not typically covered by insurance
- Convenience
- Daily drops at home; no clinic visits required after initial assessment; can address multiple allergens in a single formulation
- Safety
- No confirmed fatalities; local oral reactions common and mild; anaphylaxis case reports rare; less standardized than tablets
- Efficacy
- FDA-approved January 2020; achieves desensitization (increased threshold), not full tolerance; for peanut allergy only
- Duration
- Ongoing (desensitization maintained, not a cure)
- Cost (5yr)
- $10,000-$15,000+; insurance coverage variable
- Convenience
- Daily oral dosing at home after in-office buildup; dose escalation visits required; ongoing maintenance essential
- Safety
- Systemic reactions more common than environmental AIT; abdominal pain frequent; EoE risk; requires epinephrine prescription
- Efficacy
- Symptom relief only; no disease modification; about 12% reduction in nasal symptom scores (Matricardi 2011)
- Duration
- Ongoing (symptoms return on stopping)
- Cost (5yr)
- $300-$900 OTC
- Convenience
- Daily pill; available without prescription; no clinic visits
- Safety
- Non-sedating second-generation: generally safe; no immunological benefit; no effect on disease progression
For patients who find weekly clinic visits difficult or live far from an allergist, Curex now delivers the shot route itself as an at-home allergy shot kit (SCIT) — a personalized serum sterile-compounded to USP <797>, one weekly shot you give yourself at home, and the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff after a prescribed epinephrine auto-injector is confirmed on hand. program-specific pricing confirmed by quote, and can address multiple allergen triggers identified in your allergy test results.
Join the waitlistFrequently asked questions
What is the difference between allergy shots and sublingual immunotherapy?
Allergy shots (SCIT) deliver allergen extracts via subcutaneous injection into the upper arm, requiring clinic visits with a mandatory 30-minute observation period after each dose. Sublingual immunotherapy (SLIT) delivers allergen under the tongue — as tablets approved by the FDA for grass, ragweed, and dust mite, or as compounded drops. Both approaches drive the same core immune changes (Treg induction, IgG4 rise, mast cell desensitization), but SLIT uses 50-100 times higher doses to achieve comparable results through the oral mucosal route. SLIT has zero confirmed worldwide fatalities versus roughly 1 per 2.5 million injections for SCIT historically. SCIT retains an advantage for polysensitized patients needing custom multi-allergen formulations, as no approved tablet covers multiple unrelated allergens simultaneously.
How long does it take to see results with Curex allergy shots?
Most patients notice symptom improvement within 3 to 6 months of starting immunotherapy, often coinciding with reaching the maintenance dose for SCIT or completing the first treatment season for SLIT. The AAAAI/ACAAI Practice Parameter states that clinical improvement is usually observed within 1 year of reaching maintenance dose. However, the disease-modifying benefit — relief that persists after stopping treatment — requires at least 3 years of therapy. This same build-up-to-maintenance timeline applies to Curex's at-home allergy shot program. If no improvement occurs after 1 year at the maintenance dose with allergens correctly identified, discontinuation should be considered with your allergist.
Is allergy immunotherapy a permanent cure?
Allergy immunotherapy is disease-modifying but not a permanent cure for all patients. Durham et al. (NEJM 1999) demonstrated that 3-4 years of grass pollen SCIT produced symptom relief lasting at least 3 years after stopping treatment — with no relapse detectable versus continued maintenance patients. However, skin-test reactivity gradually returns over years, and some patients relapse, particularly those who were polysensitized. The evidence strongly suggests that a treatment duration of 3-5 years optimizes durability. Immunotherapy should not be described as a cure; many clinicians prefer the term sustained remission instead.
Who is a good candidate for allergy immunotherapy?
Strong candidates have confirmed IgE-mediated sensitization (positive skin prick test or serum-specific IgE) to clinically relevant allergens, experience moderate-to-severe symptoms despite antihistamines or nasal corticosteroids, prefer disease modification over long-term symptom medications, and are committed to a 3-5 year treatment course. Per AAAAI/ACAAI guidelines, failure of pharmacotherapy is not required before offering immunotherapy. Contraindications include severe uncontrolled asthma and pregnancy for initiation (maintenance can continue).
What SLIT tablet options are approved in the US?
Four sublingual immunotherapy tablets are currently approved by the FDA in the United States. Grastek treats timothy grass pollen for adults and children 5 and older. Ragwitek treats short ragweed pollen for adults 18 and older. Oralair treats a five-grass mix for adults and children 10-65. Odactra treats house dust mites and was recently expanded to children 5-11. Each product treats only one allergen category — a limitation for patients sensitized to multiple unrelated allergens.
How much do allergy shots cost?
Traditional in-clinic allergy shots usually run from a few hundred to several thousand dollars a year once you add allergy testing, serum, and a copay for each weekly visit. Curex's at-home program offers pricing confirmed in a current program quote with no per-visit copays. Actual cost depends on your allergens, insurance, and how long you stay in treatment.
What's in an allergy shot?
An allergy shot contains a small, purified dose of the exact allergens you tested positive for — such as pollens, dust mite, mold, or pet dander — in a sterile liquid extract. There is no drug in it; it simply exposes your immune system to gradually increasing amounts of your own triggers so it becomes less reactive over time.
Do allergy shots really work?
Yes — allergen immunotherapy is the only treatment shown to change the underlying allergy rather than just mask symptoms, and it can keep working for years after you finish. It is most effective for airborne allergies like pollen, dust mite, mold, and pet dander. It is a long-term commitment, not an instant fix.
How often do you get allergy shots?
During the build-up phase, allergy shots are given once weekly while the dose gradually increases. After you reach your maintenance dose, injections become less frequent on a schedule your allergist individualizes for you. Curex uses a conservative once-weekly build-up and does not offer rush or cluster schedules.
What are the side effects of allergy shots?
The most common side effect is a temporary local reaction — redness, itching, or swelling at the injection site — that usually settles within hours. Serious whole-body (systemic) reactions are rare but possible, which is why a prescribed epinephrine auto-injector is confirmed on hand at the injection location before every dose.
How do you get allergy shots?
You first need an allergy test to identify your specific triggers and a prescribing allergist to create your personalized serum. Curex runs this entirely from home: an online evaluation, testing, a custom extract, and live supervision through the Virtual Shot Room with trained Curex clinical staff for your first injection and each new vial or concentration. The pilot is available in select states.
Are allergy shots covered by insurance?
In-clinic allergy shots are often billable to insurance, but weekly-visit copays and testing fees can still add up to a significant yearly cost. Curex offers pricing confirmed in a current program quote, which many patients find simpler to budget than variable per-visit copays. Coverage always depends on your specific plan.
Related Articles
Are Allergy Shots Subcutaneous or Intramuscular? | Curex
Allergy shots are always subcutaneous, never intramuscular. Learn the clinical reasons why IM is avoided and what systemic reaction risks it would carry.
Read moreImmunotherapy for Allergy: How It Rewires Immunity | Curex
Immunotherapy for allergy reprograms immunity via FOXP3+ Tregs and IgG4 blocking antibodies. Learn how the immune cascade leads to lasting allergy relief.
Read moreAllergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreAllergy Immunotherapy Schedule: Visits & Timeline | Curex
Allergy immunotherapy schedule: clinic SCIT needs 57–60 visits over 3 years; at-home Curex shots need none. Compare every modality timeline.
Read moreAllergy Shot Side Effects: Per-Injection Timeline | Curex
What happens after each allergy shot? A minute-by-minute timeline from the 30-min wait to 48-hour local reactions, with safety thresholds and real data.
Read moreAllergy Shots vs Drops: Evidence-Based Comparison | Curex
Allergy shots (SCIT) vs sublingual drops (SLIT): comparable efficacy per Nelson 2015, but SLIT has zero fatalities vs 1 per 2.5M shots. Full comparison.
Read moreGet your allergy shots — without the clinic.
Curex at-home shots require a program quote. Confirm what is included in your plan — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
Program quote required · Remaining payments for shipped treatment are collected on cancellation
Curex allergy shot serum is compounded at a specialty pharmacy for each patient, and the FDA does not review compounded products for safety or efficacy.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.